Search Results 1521-1530 of 18121 for multiple%20sclerosis

  1. Study to Evaluate Safety and Preliminary Efficacy of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS) - Mayo Clinic

    This is a two-cohort, multicenter, open-label ... Not discontinued CD20 ... Systemic corticosteroids in doses greater than prednisone equivalent to 20 mg/day with ...

  2. Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea - Mayo Clinic

    at least two recurrences after a primary episode and have completed at least two rounds of standard-of-care oral antibiotic therapy or ... Taking steroids (≥ 20 ...

  3. Stroke - Doctors and departments - Mayo Clinic

    Displaying 11-20 out of 60 doctors available. Alex ... ogic disorder, Multiple sclerosis, Spinal cord injury, Spinal pain, Joint ...

  4. Stroke - Doctors and departments - Mayo Clinic

    Displaying 11-20 out of 61 doctors available. Alex ... ogic disorder, Multiple sclerosis, Spinal cord injury, Spinal pain, Joint ...

  5. Stroke - Doctors and departments - Mayo Clinic

    Displaying 11-20 out of 61 doctors available. Alex ... ogic disorder, Multiple sclerosis, Spinal cord injury, Spinal pain, Joint ...

  6. Publications - Leslie F. Thomas, M.D. - Mayo Clinic

    2020 Nov; 20 (11):3061-3071 Epub 2020 Sept 15 ... [Small cell lung cancer associated with multiple paraneoplastic syndromes]. ... 2016 Mar; 16 (3):1015-20 ...

  7. A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy - Mayo Clinic

    Must have completed last cycle of second-line induction no less than 8 weeks (56 days) and no greater than 20 weeks (140 days) prior to randomization. Must ...

  8. Overview - Cell Biology of Metastasis Laboratory - Mayo Clinic Research

    First, inflammation is a risk factor for pancreatic cancer development and contributes to increased tumor progression and metastasis in multiple cancer models.

  9. Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) - Mayo Clinic

    The purpose of this study is to compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.

  10. Dr. Daniel Saris Archives - Mayo Clinic News Network

    ... sclerosis (ALS) resulting in new therapies for ... 20 years from the disease onset. The goal of this ... two genes—ARMS2/HTRA1—are the largest ...